Dr Arvind Hundal joins Zealand Pharma
pharmafile | September 19, 2011 | Appointment | Sales and Marketing | appointment, sales and marketing
Zealand Pharma has boosted its executive management team with the appointment of Dr Arvind Hundal as chief business officer.
She joined the Danish biopharmaceutical company in 2009 as VP of business development will join the company’s Executive Management with immediate effect.
Before moving to Zealand Dr Hundal served as business development director at 7TM Pharma, and prior to that served as a member of the Strategic Planning Business Development organisation at AstraZeneca.
She has over 15 years of experience in the life sciences sector, at least 10 of which have been in a business development role, working on both in- and out-licensing across the industry from pre-seed start-up companies and spinout biotechnology to large top-tier pharmaceutical companies.
Dr Hundal has worked on deals covering a large array of compounds and technologies spanning a wide range of therapeutic areas including gastrointestinal, metabolic, cardiovascular, oncology, virology, inflammatory conditions and the central nervous system.
Zealand Pharma’s president and chief executive David Solomon said: “Arvind has been instrumental in the success of Zealand Pharma’s business development activities, most recently for the agreement that we signed with Boehringer Ingelheim in June this year.
“Active partnering is a cornerstone of our business, and I am pleased that Arvind now joins Zealand’s executive management team where her deep understanding of the international life sciences industry and her skills and broad-based experience in licensing will help to ensure that we maximise the value of our drug pipeline.”
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Myeloma UK reveals new Director of Research appointment
UK non-profit organisation Myeloma UK has selected Sarah McDonald as its new Director of Research, …
Abbott CEO to step down after 21 years
After more than two decades at the head of the company, it has emerged that …
